Geron (NASDAQ:GERN)‘s stock had its “buy” rating reaffirmed by stock analysts at MLV & Co. in a report issued on Saturday. They currently have a $6.00 price target on the stock. MLV & Co.’s price objective points to a potential upside of 55.84% from the stock’s previous close.
The analysts wrote, “Geron reiterated its target to initiate a Phase II trial of imetelstat in myelofibrosis in collaboration with Janssen in mid-2015, and to start a Phase II trial in myelodysplastic syndromes before year-end 2015. Based on the Phase II MF trial protocol, it will evaluate imetelstat at two dosages in about 200 patients who have relapsed or are refractory to treatment with a Janus Kinase inhibitor, and will measure spleen size and total symptom score as the trial’s primary endpoints.” “
A number of other analysts have also recently weighed in on GERN. Analysts at Oppenheimer initiated coverage on shares of Geron in a research note on Monday, April 20th. They set an “outperform” rating and a $5.50 price target on the stock. Separately, analysts at Zacks reiterated a “buy” rating and set a $4.50 price target on shares of Geron in a research note on Monday, March 23rd.